Cryoport has experienced remarkable growth in the past year: the company opened facilities in Amsterdam and Livingston, N.J., expanded its animal health services, hired several new employees, and announced an impressive 64% growth in FY 2018.
This growth reflects a strong business strategy in a burgeoning industry. In a new interview with BioPharma-Reporter, Cryoport President and CEO Jerrell W. Shelton shares details about the company’s new deal with Celularity, the tremendous growth of the cell and gene therapy market, and how Cryoport’s specialized monitoring and temperature-controlled logistics support hundreds of packages being transported globally every day.
- Celularity Selects Cryoport’s Temperature Controlled Logistics Solutions (April 2019)
- Biokin Pharmaceuticals Selects Cryoport’s Temperature Controlled Logistics Solutions for its Pending Phase I and Phase II Trials (March 2019)
- Cryoport Opens Global Logistics Center in Amsterdam (January 2019)